Strategic · Healthtech
4D Path closes strategic financing and expands its board
Katherine Vega Stultz becomes chair as the company advances treatment-predictive biomarkers and biopharma partnerships.
Capital and governance for the next development phase
The May 5 announcement describes a first close without disclosing the amount or naming investors. Robert J. Hombach also joins the board, adding healthcare finance and operations experience alongside Stultz’s oncology development background.
The financing supports biomarker development for company-sponsored clinical use and biopharma collaborations. The announcement pairs that research agenda with a board equipped to support clinical evidence generation and commercialization.
Funding history
Strategic · This roundUndisclosed